Sage Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Sage Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.48M	Buy	21,992 +3,423	+18%	+$463K	1.36%	20
2026 Q1	$2.37M	Sell	18,569 -104	-0.6%	-$13K	1.12%	25
2025 Q4	$2.28M	Sell	18,673 -669	-3%	-$76.7K	1.05%	25
2025 Q3	$1.94M	Sell	19,342 -1,961	-9%	-$177K	0.87%	30
2025 Q2	$1.77M	Sell	21,303 -195	-0.9%	-$15.6K	0.85%	33
2025 Q1	$1.74M	Sell	21,498 -404	-2%	-$36.1K	0.95%	27
2024 Q4	$1.97M	Sell	21,902 -1,735	-7%	-$168K	1%	25
2024 Q3	$2.34M	Sell	23,637 -904	-4%	-$88.8K	1.12%	24
2024 Q2	$2.28M	Sell	24,541 -145	-0.6%	-$13K	1.2%	24
2024 Q1	$2.34M	Hold	24,686	–	–	1.27%	24
2023 Q4	$2.2M	Buy	+24,686	New	+$1.83M	1.32%	23

Other funds holding XBI

PSP Research Newtown Square, Pennsylvania $188M AUM

AAS

Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return

WAM

Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return

RFM

Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return

NHFG

New Harbor Financial Group Worcester, Massachusetts $633M AUM 37.53% 1-Year Est. Return

MFS

Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

LRPA

L. Roy Papp & Associates Phoenix, Arizona $951M AUM 29.05% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $132M AUM 24.1% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return

EWM

Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

Sage Capital Management's XBI Position: Q2 2026 in Review

Sage Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 18% in Q2 2026, buying an estimated $463K and bringing the position to 21,992 shares worth $3.48M. The position accounts for 1.36% of the portfolio, ranked #20.

Sage Capital Management first reported a position in XBI in Q4 2023 and has held it in 11 quarters since. 293 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Sage Capital Management held 21,992 shares of State Street SPDR S&P Biotech ETF worth $3.48M as of Q2 2026.
Sage Capital Management bought 3,423 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $463K.
State Street SPDR S&P Biotech ETF made up 1.36% of Sage Capital Management's portfolio in Q2 2026, its #20 holding.
Sage Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and has held it in 11 quarters since.
293 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Sage Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.